Sentieon is a technology company.
Sentieon has raised $4.0M across 1 funding round.
Sentieon has raised $4.0M in total across 1 funding round.
Sentieon has raised $4.0M in total across 1 funding round.
Sentieon's investors include AMR Action Fund, Mission BioCapital.
Sentieon is a bioinformatics technology company that develops highly optimized software tools for secondary analysis of genomics data from next-generation sequencing (NGS), enabling precision medicine through fast, accurate, and cost-efficient processing.[1][2] Its core products, such as DNAseq, DNAscope, TNseq, and TNscope, serve genomics researchers, sequencing platforms, and precision medicine organizations by providing drop-in replacements for tools like GATK, BWA-MEM, and MuTect2, achieving up to 10x faster processing with superior accuracy on short and long reads from any sequencer.[2][3][4] Sentieon solves key bottlenecks in variant calling for germline and somatic analysis, processing over 4.9 million samples for 1,860+ clients with metrics like <30-minute turnaround for 30x whole-genome sequencing (WGS) and over 1 billion core hours accumulated, demonstrating strong growth via partnerships with Ultima Genomics, Element Biosciences, MGI, and AWS.[1][2][5][6]
Sentieon was incorporated in July 2014 as a team of engineers with expertise in image processing, telecom, computational lithography, large-scale data mining, and bioinformatics.[1] Drawing from their backgrounds in modeling, optimization, machine learning, and high-performance computing, the founders focused on creating accelerated algorithms to address inefficiencies in NGS secondary analysis.[1][5][7] Early traction came through validated tools matching GATK best practices but with 10x speed gains, leading to partnerships like QIAGEN (2018) and Golden Helix (2017), and award-winning performance in precisionFDA challenges.[1][3] Pivotal moments include collaborations with Ultima Genomics and Element Biosciences in 2022, validating Sentieon's tools on novel sequencing platforms.[5][7]
Sentieon's tools stand out in bioinformatics through algorithmic and implementation excellence:
Sentieon rides the genomics boom driven by falling sequencing costs (e.g., Ultima's $1/Gb) and surging demand for precision medicine, where secondary analysis bottlenecks limit scalability.[2][5][6] Its timing aligns with multi-omics integration and long-read tech from platforms like PacBio and Ultima, enabling high-throughput WGS/WES at population scale amid trends like AI-enhanced calling and cloud HPC.[1][5][7] Market forces favoring Sentieon include NGS data explosion (petabyte-scale cohorts) and need for cost-effective, accurate tools amid compute shortages; it influences the ecosystem by partnering with sequencers (MGI, Element) and cloud providers (AWS), standardizing efficient pipelines and accelerating discoveries in oncology, conservation, and rare diseases.[1][2][6]
Sentieon is poised to dominate NGS secondary analysis as sequencing volumes hit exabyte scales, with expansions into multi-omics, real-time processing, and deeper AI integration via models like those for Ultima.[2][5] Trends like federated learning for privacy-preserving cohorts and ARM/edge computing will amplify its efficiency edge, potentially capturing more of the $10B+ bioinformatics market.[6] Its influence may evolve from tool provider to ecosystem enabler, powering global biobanks and personalized therapies—reinforcing its mission to deliver precision data for precision medicine in an era of ubiquitous genomics.[1][2]
Sentieon has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in April 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2014 | $4.0M Series A | AMR Action Fund, Mission BioCapital |